The translocation t(2;11)(p21;q23) without MLL gene rearrangement-a possible marker of good prognosis in myelodysplastic syndrome patients

Hematological Oncology

Volumn 32, Issue 2, 2014, Pages 82-86

  Dvorak, Pavel ^a   Lysak, Daniel ^a   Vokurka, Samuel ^a   Michalova, Kyra ^b,c   Sarova, Iveta ^b,c   Jonasova, Anna ^c   Hruba, Martina ^a   Rykovska, Anna ^a   Subrt, Ivan ^a,c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Good prognosis; Karyotype; Myelodysplastic syndromes; T(2; 11)(p21; q23)

Indexed keywords

LENALIDOMIDE; MIXED LINEAGE LEUKEMIA PROTEIN;

ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW CELL; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CYTODIAGNOSIS; CZECH REPUBLIC; DYSPLASIA; GENE REARRANGEMENT; GENE TRANSLOCATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MEGAKARYOPOIESIS; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; TRISOMY 8;

GOOD PROGNOSIS; KARYOTYPE; MYELODYSPLASTIC SYNDROMES; T(2;11)(P21;Q23);

ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 2; GENE REARRANGEMENT; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 84901952041     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2089     Document Type: Article

References (13)

1. Swerdlow SH, Capo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC: Lyon, 2008; p. 439.
2. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87: 692-701.
3. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385-4395.
4. Deeg HJ, Scott BL, Fang M, et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012; 120: 1398-1408.
5. Solé F, Luño E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005; 90: 1168-1178.
6. Kardon N, Shulman P, Deggnan T, Budman DR, Davis J, Vinciguerra V. Cytogenetic findings in dysmyelopoietic syndrome. Cancer 1982; 50: 2834-2838.
7. Mitelman F, Johansson B, Mertens F (eds). Mitelman database of chromosome aberrations and gene fusions in cancer, 2012. http://cgap.nci.nih.gov/Chromosomes/Mitelman
8. ISCN. An international system for human cytogenetic nomenclature. Shaffer LG, McGowan-Jordan J, Schmid M (eds). S. Karger: Basel; 2013.
9. Fleischman EW, Reshmi S, Frenkel MA, et al. MLL is involved in a t(2;11)(p21;q23) in a patient with acute myeloblastic leukemia. Genes Chromosomes Cancer 1999; 24: 151-155.
10. Bousquet M, Quelen C, Rosati R, et al. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med 2008; 205: 2499-2506.
11. Surdziel E, Cabanski M, Dallmann I, et al. Enforced expression of miR-125b affects myelopoiesis by targeting multiple signalling pathways. Blood 2011; 117: 4338-4348.
12. Chaudhuri AA, So AY, Mehta A, et al. Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A. Proc Natl Acad Sci U S A 2012; 109: 4233-4238.
13. Gozzetti A, Tozzuoli D, Crupi R, Raspadori D, Fabbri A, Lauria F. A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement. Cancer Genet Cytogenet 2003; 144: 177-178.